Resources

Research note by Capital Networks following the milestone immunogenicity data which keeps Avacta on track for first therapeutic Affimer into the clinic. 

Category:

See also, Avacta's presentation: Immunogenicity Data: A Key Milestone

Category:

Analysis and commentary by Dr Riccardo Lowi who originally trained as a doctor and chose to apply his knowledge in the commercial setting as a healthcare equity analyst.

Category:

See the latest note from Hardman & Co about Avacta. 

Category:

Pages